Bofu Laser Secures Nearly RMB 100 Million Series A Funding to Accelerate Domestic High-End Aesthetic Laser Equipment Development and Global Expansion

VCBeat has learned at the earliest opportunity,Nanjing BaifuObtained byYuanBio Venture CapitalLead Investor, Existing ShareholdersAurora Venture CapitalCo-investmentSeries A Financing of Nearly RMB 100 Million, the funds will be used for domestic mid-to-high-end medical aesthetic optoelectronic devices, such as picosecond lasers, erbium lasers, alexandrite lasers, and dye lasers.Clinical Registration in China and Global Market Promotion。

The founding team of Baifu Laser has been deeply engaged in the medical aesthetic optoelectronic equipment industry for over a decade, making it a leading ChineseTechnology-Driven High-End Aesthetic Medicine Optoelectronic Device Enterprise. The company is currently dedicated to the independent R&D, production, sales, and scientific research services of innovative products in the fields of dermatology, plastic surgery, rehabilitation medicine, and general health. At present, some of its mid-to-high-end products have achieved breakthroughs in domestic production. It has independently developed a series of products, including ND:YAG Q-switched lasers, 1064 nm and 755 nm alexandrite long-pulse lasers, 2940 nm erbium lasers, 1064 nm and 532 nm picosecond lasers, 595 nm pulsed dye lasers, and 1927 nm thulium lasers, with relevant technical indicators reaching a leading level in China.(See also: "Nanjing Baifu: Benchmarking Against Global Giants to Become the Leader in High-End Domestic Medical Aesthetic Laser Equipment")

In terms of commercialization, leveraging founder Jia Yangchun’s educational background and his extensive professional experience and resource accumulation in overseas sales, Nanjing Baifu Laser Technology Co., Ltd. has adopted a strategy of targeting differentiated markets. The company’s products are primarily export-oriented, focusing onSpanish-speaking Countries and Middle Eastern Countries Markets, it soon achieved independent “hematopoietic” capability. Meanwhile, the company has progressively increased its investments in the Chinese market, establishing a development model that places equal emphasis on technology and market expansion while synchronizing domestic and international operations.(See also: “Exclusive Interview with Jia Yangchun of Nanjing Baifu: Globalization of Domestic Medical Devices Is Imperative, Ushering in the ‘Golden Age’ of Aesthetic Laser Technology”)

Regarding this round of financing,Jia Yangchun, Founder of Baifu Laser“Thank you to YuanBio Venture Capital and Northern Light Venture Capital for their trust. We will double our efforts to drive the company’s rapid overall development.”

Gu Minlei, Partner at YuanBio Venture Capitalstated: “Benefiting from the rapid growth of the medical aesthetics market over the past decade, numerous publicly listed companies with market capitalizations exceeding RMB 10 billion have emerged, demonstrating the broad prospects for the future of the medical aesthetics industry. Among these, photoelectric medical aesthetic treatments are increasingly favored by consumers due to their non-invasive nature and safety profile. However, in this sector, Chinese manufacturers lag significantly behind overseas imported brands, particularly in high-end medical aesthetic equipment, where there is still a gap in domestic manufacturing capabilities. Baifu Laser has fully demonstrated its product performance and ability to expand into overseas markets through its historical sales record. We are optimistic about the team’s continuous innovation and engineering capabilities at the intersection of medicine and engineering, and we envision Baifu becoming a benchmark for domestically produced high-end laser medical aesthetic devices.”

Deng Feng, Founding Managing Partner of Northern Light Venture Capital“YuanBio Venture Capital is highly optimistic about the growth potential of the global medical aesthetics market. As living standards rise and global aging deepens, consumer demand for beauty and anti-aging treatments is becoming increasingly strong. The team at Nanjing Baifu Laser Technology Co., Ltd. boasts years of industry experience and has continuously invested in R&D, achieving a breakthrough in the domestic production of high-end medical aesthetic laser technologies. We are delighted to support the Baifu team as they pioneer entry into the blue ocean of photoelectric devices for medical aesthetics, and we look forward to seeing the team achieve successive breakthroughs across various product categories, thereby filling technological gaps in China.”

YuanBio Venture Capital is an investment firm focused on the early and growth stages of the healthcare sector. Headquartered in Suzhou BioBAY, it extends its reach globally. To date, YuanBio has invested in over 140 outstanding companies in the life and health sectors, covering four key areas: novel drug development, medical devices, in vitro diagnostics and precision medicine, as well as healthcare services. The firm has achieved substantial investment returns, with 14 of its portfolio companies having listed on capital markets such as the Hong Kong Stock Exchange and the STAR Market. YuanBio has been repeatedly recognized as one of the Top 10 venture capital funds in China’s healthcare sector and as one of the most active healthcare investment institutions in China. By bringing together seasoned professional investors and a global team of top-tier scientific advisors, YuanBio possesses extensive experience in entrepreneurship, venture capital, and corporate operations within the biopharmaceutical industry and beyond. Leveraging its professionalism, focus, and abundant industry resources, YuanBio is committed to becoming one of the most successful healthcare and pharmaceutical venture capital funds in China.

Northern Light Venture Capital, founded by Mr. Deng Feng in 2005, is a venture capital firm dedicated to “empowering world-class Chinese entrepreneurs and cultivating world-class Chinese enterprises.” The firm currently manages six U.S. dollar funds and four RMB funds, with assets under management exceeding RMB 30 billion. It has long focused on investing in high-potential early-stage companies driven by technological innovation. To date, Northern Light Venture Capital has invested in more than 400 outstanding companies across the sectors of new technologies, healthcare, and new consumption.

Aurora Venture Capital entered the healthcare sector in 2009. Over the past decade, it has invested across multiple sub-sectors, including innovative drugs and biotechnology, medical devices, IVD, life sciences, digital health, and novel healthcare services. Aurora has invested in more than 90 innovative healthcare companies, such as CITIC Pharma, BGI Genomics, Burning Rock Biotech, Zeltis Pharmaceuticals, iRay Technology, Conatus Pharmaceuticals, Cytek Biosciences, Guoke Hengtai, Taimei Medical Technology, Belief BioMed, Yidao Biologics, Eastern Speech Therapy, and Coyote Bioscience. The firm is committed to advancing technological development and social progress, working hand in hand with entrepreneurs.